Everolimus Tablet
Product Images NDC 70377-012

11 FDA label images from Biocon Pharma Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 70377-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel Package Label 2.5 mg (2 5 mg Bottle Label)

Principal Display Panel Package Label 2.5 mg (2 5 mg Bottle Label)
Label for Everolimus Tablets 2.5 mg oral tablets, containing 30 tablets per package. Produced by Biocon Pharma Inc., with manufacturing in Bengaluru, India. The label includes storage instructions, dosage note, and barcode. It specifies the product as prescription only and highlights the package as child-resistant.*
FDA Label Image

Principal Display Panel Package Label 5 mg (5 mg Bottle Label)

Principal Display Panel Package Label 5 mg (5 mg Bottle Label)
Packaging label for Everolimus Tablets 5 mg oral tablets by Biocon Pharma Inc. The label includes NDC 70377-011-11, indicates 30 tablets per package, and displays storage instructions at 25°C with a child-resistant warning. Manufacturer and labeler details for Biocon Pharma Inc., New Jersey, USA, and Biocon Pharma Limited, Bengaluru, India, are also shown along with a barcode and serialization area.*
FDA Label Image

Principal Display Panel Package Label 7.5 mg (7 5 mg Bottle Label)

Principal Display Panel Package Label 7.5 mg (7 5 mg Bottle Label)
The label for Everolimus Tablets 7.5 mg oral tablets, containing 30 tablets per package. It features the NDC number 70377-012-11 and includes dosage storage instructions. The label shows manufacturing details for Biocon Pharma Inc., located in Iselin, NJ, USA, and manufacturing site in Bengaluru, India. The Biocon logo appears on the label, which also states the package is child-resistant.*
FDA Label Image

Principal Display Panel Package Label 10 mg (10 mg Bottle Label)

Principal Display Panel Package Label 10 mg (10 mg Bottle Label)
Everolimus Tablets 10 mg oral tablets packaging label with NDC 70377-013-11. Contains 30 tablets per package. Label shows storage instructions, manufacturer Biocon Pharma Inc., and a barcode. Includes child-resistant package notice and space for batch serialization coding with GTIN, serial number, expiration date, and lot number data placeholders.*
FDA Label Image

Figure 4: Kaplan-meier Curves For Progression-free Survival In Rcc In Record-1 (Figure 4)

Figure 4: Kaplan-meier Curves For Progression-free Survival In Rcc In Record-1 (Figure 4)
A Kaplan-Meier survival curve chart comparing the probability of survival over 14 months for patients treated with Everolimus versus placebo. The chart includes hazard ratio and median survival times, showing Everolimus with a higher survival probability than placebo over time. Symbols denote censoring times for both groups.*
FDA Label Image

Everolimus Structural Formula (Everolimus Structure)

Everolimus Structural Formula (Everolimus Structure)
Chemical structure of the active ingredient everolimus, displayed as a complex molecular diagram with multiple rings, bonds, and functional groups, corresponding to its molecular composition in the EVEROLIMUS oral tablet formulation by Biocon Pharma Inc.*
FDA Label Image

Figure 1: Kaplan-meier Progression-free Survival Curves (investigator Radiological Review) (Figure 1)

Figure 1:  Kaplan-meier Progression-free Survival Curves (investigator Radiological Review) (Figure 1)
A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time in months. The chart compares two groups: Everolimus 10 mg plus exemestane (black solid line with square markers) and placebo plus exemestane (dashed gray line with triangle markers). Censoring times are marked with open squares and triangles. The hazard ratio is 0.45 with 95% confidence interval [0.38, 0.54]. Median survival times for Everolimus 10 mg plus exemestane is 7.8 months and for placebo plus exemestane is 3.2 months. The logrank p-value is less than 0.0001.*
FDA Label Image

Principal Display Panel Package Label 2.5 mg Rx Only Ndc 70377-010-22 Everolimus Tablets Each Tablet Contains 2.5 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets (2 5 mg Carton Label)

Principal Display Panel Package Label 2.5 mg Rx Only		Ndc 70377-010-22 Everolimus Tablets Each Tablet Contains 2.5 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets (2 5 mg Carton Label)
Packaging label for Everolimus Tablets 2.5 mg by Biocon Pharma Inc. The carton contains 28 tablets. Key details include the NDC number 70377-010-22, dosage strength 2.5 mg, oral route, and batch coding area. The label highlights storage instructions and manufacturer information printed on the sides.*
FDA Label Image

Principal Display Panel Package Label 5 mg Rx Only Ndc 70377-011-22 Everolimus Tablets Each Tablet Contains 5 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets (5 mg Carton Label)

Principal Display Panel Package Label 5 mg Rx Only		Ndc 70377-011-22 Everolimus Tablets Each Tablet Contains 5 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets (5 mg Carton Label)
The packaging label for Everolimus Tablets 5 mg oral tablets by Biocon Pharma Inc. The carton contains 28 tablets, organized as 4 blister cards of 7 tablets each. The label states each tablet contains 5 mg of everolimus and includes storage instructions and manufacturer details. The design features the Biocon logo with text in blue and brown on a white background with blue and pink accents.*
FDA Label Image

Principal Display Panel Package Label 7.5 mg Rx Only Ndc 70377-012-22 Everolimus Tablets Each Tablet Contains 7.5 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets. (7 5 mg Carton Label)

Principal Display Panel Package Label 7.5 mg Rx Only		Ndc 70377-012-22  Everolimus Tablets Each Tablet Contains 7.5 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets. (7 5 mg Carton Label)
Packaging label for Everolimus Tablets 7.5 mg by Biocon Pharma Inc. The label shows 28 tablets per carton with NDC 70377-012-22. It includes directions for storage and notes that each tablet contains 7.5 mg everolimus. The label features the Biocon logo and states prescription use only (Rx only).*
FDA Label Image

Principal Display Panel Package Label 10 mg Rx Only Ndc 70377-13-22 Everolimus Tablets Each Tablet Contains10 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets (10 mg Carton Label)

Principal Display Panel Package Label 10 mg Rx Only		Ndc 70377-13-22 Everolimus Tablets Each Tablet Contains10 mg Everolimus 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets (10 mg Carton Label)
Packaging label for Everolimus Tablets 10 mg by Biocon Pharma Inc. The carton contains 28 oral tablets, presented in 4 blister cards of 7 tablets each. The label displays the NDC 70377-013-22 and emphasizes the 10 mg dosage strength. Storage and usage information, manufacturer details, and the Biocon logo are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.